Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Highlights from IMW 2019 Part I

Francesca Gay and Katja Weisel • 25 Sep 2019
IMW 2019
Multiple Myeloma Antibodies Carfilzomib Daratumumab Dexamethasone Isatuximab Rituximab Thalidomide
CASSIOPEIA

Katja Weisel, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, and Francesca Gay, MD, University of Turin, Turin, Italy, discuss highlights from the International Myeloma Workshop (IMW) 2019, held in Boston, MA, with particular focus on the CASSIOPEIA trial (NCT02541383) and the future of measurable residual disease (MRD) in myeloma treatment.

More from Francesca Gay

1:46
FORTE: MRD by MFC or NGS in myeloma
Francesca Gay • 14 Dec 2020
1:30
MRD: Paving the way for future clinical trials in myeloma
Francesca Gay • 14 Dec 2020
0:45
FORTE: KRd versus KCd treatment for myeloma
Francesca Gay • 14 Dec 2020
1:06
MRD evaluation by MFC and NGS for MM
Francesca Gay • 7 Dec 2019

More from Katja Weisel

1:02
DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myeloma
Katja Weisel • 3 Jun 2023
1:28
Ocular adverse events with ADCs
Katja Weisel • 10 Sep 2021
3:02
ADCs for the treatment of myeloma
Katja Weisel • 10 Sep 2021
1:43
MRD: from clinical trials to clinical practice
Katja Weisel • 10 Sep 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals